The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
The Chemours CompanyNYSE: CC
EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026
EPS (Basic) remains negative
Q2 FY2026 EPS (Basic) was -$1.81, compared with -$2.54 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.
Context
- EPS (Basic) increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 5 analysts of $0.83 (+132.2%) for the fiscal year ending Dec 2026, a step up from the -543.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$1.81-852.6% QoQ
- Last fiscal yearDec 2025
- -$2.57-543.1% YoY
- LTMJun 2026
- -$2+28.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +28.7% | -33.4% | -62.2 pp |
| 1 year | -543.1% | +132.2% | +675.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (2.57) USD
- Year-over-year change
- -543.1%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.57) | -543.1% |
| FY2024 | 2024-12-31 | 0.58 | +136.3% |
| FY2023 | 2023-12-31 | (1.60) | -143.0% |
| FY2022 | 2022-12-31 | 3.72 | +0.8% |
| FY2021 | 2021-12-31 | 3.69 | — |
EPS (Basic) vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 EPS (Basic) of -$2 is the 17th highest of the 19 companies compared; the peer median is $1.39.
- Its year-over-year change of +28.6% is the 11th highest of 19, against a peer median of +56.0%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $15.56 | +10.2% | +20.9% | |
| LTM Jun 2026 | $7.02 | +58.5% | +17.0% | |
| LTM Sep 2026 | $5.62 | +1224.0% | — | |
| LTM Sep 2026 | $3.98 | +205.3% | — | |
| LTM Jun 2026 | $3.73 | +16.6% | -1.8% | |
| LTM Aug 2026 | $3.64 | +1448.1% | -6.2% | |
| LTM Jun 2026 | $3.61 | -53.2% | +18.5% | |
| LTM Sep 2026 | $2.39 | +234.4% | -38.6% | |
| LTM Jun 2026 | $1.63 | -20.1% | +26.2% | |
| LTM Jun 2026 | $1.14 | +106.1% | — | |
| LTM Jun 2026 | $1.09 | +170.8% | — | |
| LTM Sep 2026 | $0.85 | -14.6% | +1.3% | |
| LTM Sep 2026 | $0.4 | +111.9% | -25.6% | |
| LTM Mar 2026 | $0.14 | +243.7% | — | |
| LTM Mar 2026 | -$1.19 | -729.8% | — | |
| LTM Mar 2026 | -$1.6 | -447.8% | — | |
| LTM Jun 2026 | -$2 | +28.6% | — | |
| LTM Jun 2026 | -$2.2 | -515.1% | — | |
| LTM Sep 2026 | -$3.47 | +53.5% | — | |
| Peer median (excluding CC) | $1.39 | +56.0% | +1.3% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.35B | 6.83B | 6.08B | 5.78B | 5.81B |
| Cost of Revenue | 4.96B | 5.22B | 4.77B | 4.63B | 4.91B |
| Gross Profit | 1.38B | 1.62B | 1.31B | 1.15B | 902M |
| Gross Margin | 21.8% | 23.7% | 21.5% | 19.9% | 15.5% |
| Research & Development | 107M | 118M | 108M | 109M | 108M |
| Selling, General & Admin | 592M | 710M | 1.29B | 585M | 799M |
| Operating Expenses | 707M | 830M | 1.43B | 708M | 907M |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| EBITDA | 1.18B | 1.2B | 197M | 692M | 332M |
| EBITDA Margin | 18.6% | 17.5% | 3.2% | 12.0% | 5.7% |
| Operating Income | 674M | 786M | (123M) | 443M | (5M) |
| Operating Margin | 10.6% | 11.5% | -2.0% | 7.7% | -0.1% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 185M | 163M | 208M | 264M | 269M |
| Other Income / Expenses | 2M | (45M) | (195M) | (316M) | (272M) |
| Income Before Tax | 676M | 741M | (318M) | 127M | (277M) |
| Pre-Tax Margin | 10.7% | 10.8% | -5.2% | 2.2% | -4.8% |
| Income Tax Expense | 68M | 163M | (81M) | 41M | 109M |
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Net Margin | 9.6% | 8.5% | -3.9% | 1.5% | -6.6% |
| EPS (Basic) | 3.69 | 3.72 | (1.60) | 0.58 | (2.57) |
| EPS (Diluted) | 3.60 | 3.65 | (1.60) | 0.57 | (2.56) |
| Weighted Avg Shares | 164.94M | 155.36M | 148.91M | 149.49M | 150.35M |
| Weighted Avg Shares (Diluted) | 168.7M | 158.3M | 148.91M | 150.01M | 150.55M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.